pioglitazone / Generic mfg. - LARVOL DELTA

Pioglitazone Prevents the Blunted Counterregulatory Response Induced by Recurrent Hypoglycemia (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Hypoglycemia • Metabolic Disorders

Tirzepatide and Pioglitazone Combination Therapy Synergistically Improves Insulin Sensitivity and Adipose Tissue Remodeling (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Combination therapy • Metabolic Disorders

Efficacy of Pioglitazone as Adjuvant Therapy in Type 1 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Retrospective data • Review • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

PLASMA NEURON-DERIVED EXTRACELLULAR VESICLES REVEAL GLP1 AND PPARG TREATMENT RESPONSE (ADPD 2026) - "GLP-1 agonists and other metabolic interventions, such as pioglitazone, have been proposed as potential therapeutic options...In the other, middle-aged individuals at genetic risk for AD (N = 15) were treated with liraglutide, a GLP-1 receptor agonist... NDEVs ability to connect treatment-induced molecular changes with clinical outcomes highlights their potential as biomarkers to monitor therapy. This approach has translational applications in metabolic intervention across neurological diseases."

CNS Disorders • Depression • PPARG • PTEN • RPS6

Comparative Efficacy of Pioglitazone, Saroglitazar, and Silymarin on Biochemical and Histopathological Hepatic Outcomes in a Wistar Rat Model of Non-alcoholic Fatty Liver Disease and Their Correlation With Insulin Sensitivity. (PubMed, Cureus) - " Saroglitazar demonstrated the most comprehensive protective effects against NAFLD progression, surpassing pioglitazone and silymarin in biochemical, histological, and insulin resistance parameters. Its dual PPAR‑α/γ activity may offer a more effective therapeutic approach, supporting further translational evaluation in NAFLD management."

Journal • Preclinical • Dyslipidemia • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT03006172 Background: INAVO, a highly potent and selective PI3Kα inhibitor that also promotes degradation of mutated p110α, is approved by the FDA in combination with PALBO + fulvestrant (FULV) for PIK3CA-mutated, HR+, HER2–, endocrine-resistant advanced BC... Adults ≥ 18 years of age received INAVO alone (Arm A), + letrozole (LET) + PALBO (Arm B), + LET (Arm C), + FULV (Arm D), + FULV + PALBO (Arm E), or + FULV + PALBO + primary prophylactic metformin (Arm F)...The most common anti-HG medications were metformin (52.7%; biguanide; concomitant use in Arm F excluded), empagliflozin (25.5%; SGLT-2 inhibitor), sitagliptin (22.7%; DPP-4 inhibitor), and pioglitazone (13.6%; thiazolidinedione); insulin was used in 8.2% of pts... A high proportion of prediabetic/obese pts were included in GO39374. In most of these pts, HG was manageable with dose interruptions and oral anti-HG medications, most commonly metformin. Data support the use..."

Clinical • Combination therapy • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Obesity • Oncology • Solid Tumor • HER-2 • PIK3CA

Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice. (PubMed, Geroscience) - "This study underscores the importance of rigorous, multi-site testing and highlights the challenges of translating promising initial findings into consistent lifespan benefits at other doses or with alternate starting ages. These results suggest that timing and dosage are critical variables in aging intervention studies and reinforce the need for cautious interpretation of single-site or single-cohort findings."

Journal • Preclinical

EPIDOTE: A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (clinicaltrials.gov) - P4 | N=133 | Completed | Sponsor: Celltrion Pharm, Inc. | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Is there still room for pioglitazone in contemporary type 2 diabetes management? (PubMed, Cardiovasc Diabetol) - "Despite recognized adverse effects, pioglitazone retains clinical relevance due to its glycaemic efficacy, potential cardio-hepatic benefits, and low cost, particularly in health-care systems with limited access to newer agents. Rather than being interchangeable, pioglitazone and GLP-1RA occupy complementary positions within the current therapeutic landscape, underscoring the importance of individualized treatment selection."

Biomarker • Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

PCOS HOMA IR: Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Mst.Sumyara Khatun

New trial • Polycystic Ovary Syndrome

Editorial: Exploiting non-oncogene addiction for overcoming drug resistance in metastatic tumors. (PubMed, Front Pharmacol) - No abstract available

Journal • CNS Disorders • Oncology • Psychiatry

Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial. (PubMed, Nat Commun) - P1 | "This study was supported by the Ira T. Discovery Fund and the Peter and Carmen Lucia Buck Foundation Myositis Discovery Fund. Clinical Trials Registration: NCT03440034."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Immunology • Infectious Disease • Metabolic Disorders • Musculoskeletal Pain • Myositis • Novel Coronavirus Disease • Pain • PPARGC1A

SGLT2i, Pioglitazone, and Ketone Production in T2D (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: The University of Texas Health Science Center at San Antonio | Initiation date: Feb 2026 ➔ Jul 2026

Trial initiation date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A nurse practitioner's guide to metabolic dysfunction‑associated steatotic liver disease: From diagnosis to management. (PubMed, J Am Assoc Nurse Pract) - "Pharmacologic options remain limited, although vitamin E and pioglitazone may benefit select patients. Furthermore, emerging therapies are under investigation. This article presents a case of MASLD in a patient with metabolic comorbidities and persistently elevated aminotransferases, illustrating the significance of focused assessments and highlighting the role of nurse practitioners in screening, lifestyle counseling, early intervention, and longitudinal follow-up to prevent disease progression and improve outcomes."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Fibrosis • Genetic Disorders • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Obstructive Sleep Apnea • Oncology • Portal Hypertension • Respiratory Diseases • Sleep Disorder • Solid Tumor • Type 2 Diabetes Mellitus

Bladder Cancer Risk with Pioglitazone Use: Implications for Bladder Cancer Monitoring and Treatment (AUA 2026) - No abstract available

Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed/refractory neoplasias. (PubMed, Front Pharmacol) - "Tumor tissue editing regimen for 13 r/r tumor types, carcinomas, sarcomas and hematologic neoplasias, included in 15 phase I/II trials, nuclear/cytokine receptor agonists, pioglitazone, plus/minus dexamethasone or all-trans retinoic acid or interferon-α to counterbalance tumor tissue homeostasis and reprogramming of cancer hallmarks, stress response inhibitors, COX-2 inhibitor, everolimus, lenalidomide, or clarithromycin, and a stress response inducer, low-dose metronomic chemotherapy with treosulfan, trofosfamide, capecitabine, or azacitidine. Thus, editing approaches provide a template for controlling metastatic r/r tumors. In the future, diagnostics of NOA networks and transcription factors involved in tumor tissue addiction may be as valuable for therapy selection as histological/molecular genetic tumor typing for the establishment of personalized hematology/oncology."

Journal • Review • Acute Myelogenous Leukemia • Angiosarcoma • CNS Disorders • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Psychiatry • Sarcoma • Solid Tumor

Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate (clinicaltrials.gov) - P4 | N=62 | Recruiting | Sponsor: PAEC General Hospital, Islamabad

New P4 trial • Infertility • Polycystic Ovary Syndrome • Sexual Disorders

Successful treatment of a patient with metastatic gastrointestinal stromal tumor harboring dual KIT exon 9 and 17 mutations with combination of avapritinib, imatinib, and pioglitazone (DKK 2026) - "A relapse occurred in 2018, leading to guideline-based treatment with intermittent administration of sunitinib, regorafenib, and ripretinib...However, this combination caused angiodysplastic bleeding as a side effect, which was managed through off-label bevacizumab treatment...In personalized oncology, traditional trials face challenges with a small number of participants. Moreover, the vast majority of treatments remain unpublished, necessitating the development of new digital AI-supported platforms for collecting real-world data on innovative off-label treatments, thus enabling the development of decision support in personalized oncology for multidisciplinary teams."

Clinical • Metastases • Stroma • Chronic Myeloid Leukemia • Gastrointestinal Stromal Tumor • Hematological Malignancies • Leukemia • Oncology • Sarcoma • HIF1A • KIT

A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial

Computational discovery of precision therapeutics for hidradenitis suppurativa. (PubMed, bioRxiv) - "These results show that unbiased data-driven precision medicine approaches can identify novel therapies for HS and can serve more generally as a model approach for therapeutic discovery in other chronic inflammatory diseases. Data-driven precision medicine approach identifies sirolimus, pioglitazone, and fulvestrant as novel therapies for hidradenitis suppurativa."

Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • Pain

Unveiling an Uncommon Complication: Pleural Effusion Secondary to Pioglitazone Use. (PubMed, J Community Hosp Intern Med Perspect) - "The effusion resolved completely following discontinuation of the drug. This case underscores the importance of early recognition of drug-induced pleural effusion and timely cessation of the offending agent to prevent morbidity."

Journal • Pleural effusion • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Respiratory Diseases • Type 2 Diabetes Mellitus • PPARG

Diagnosis and future treatments of adolescent PCOS (ISGE 2026) - "In girls without obesity, pilot studies showed that a low-dose combination of three generics [spiomet: spironolactone (spi, 50 mg/d); pioglitazone (pio, 7.5 mg/d) and metformin (met, 850 mg/d)] can reduce ectopic fat and androgen excess and also raise insulin sensitivity and ovulation rate, thereby frequently reverting the entire PCOS phenotype. Persistence of menstrual irregularity associated with failure to stabilize body weight and to reduce hepatic fat and insulin resistance. Unblinding will disclose whether responders received predominantly one of the active medications; such medication may then hold the potential to become a first pharmacological treatment for adolescent PCOS."

Genetic Disorders • Obesity • Polycystic Ovary Syndrome • Women's Health

High risk of potential resmetirom-drug interactions in older adults with metabolic dysfunction-associated steatotic liver disease – a modelling analysis using data from the ASPREE trial (EASL-SLD 2026) - "Drugs evaluated included statins, gemfibrozil, verapamil, amiodarone, clopidogrel, pioglitazone, rosiglitazone, fluoxetine, olanzapine, and leflunomide. Conclusion MASLD was common in older adults, and when modelling risk of potential DDIs with potential resmetirom prescribing there was a high risk of both statin and non-stain resmetirom-drug interactions. Clinicians should be alert for potential interactions and consider increased monitoring or resmetirom dose adjustment depending on the nature of the interaction(s)."

Clinical • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

A halogenated pregnenolone analogue suppresses HepG2 proliferation and induces apoptosis via PPARγ regulation. (PubMed, RSC Med Chem) - "Western blots using a PPARγ agonist (pioglitazone) and antagonist (T0070907) validated its crucial role in mediating compound 20-induced apoptosis in HepG2 cells...Furthermore, a CETSA assay provided additional support, confirming that compound 20 enhances PPARγ's thermal stability. Collectively, these findings strongly suggest that compound 20 inhibits HepG2 proliferation and promotes HepG2 apoptosis via PPARγ modulation, positioning it as a promising lead compound for hepatocellular carcinoma treatment."

IO biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • BAX • BCL2 • CASP3 • CASP8 • CASP9 • PPARG

2025-523266-24-00: A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo (clinicaltrialsregister.eu) - P1/2 | N=60 | Not yet recruiting | Sponsor: I.F.O. Istituti Fisioterapici Ospitalieri

New P1/2 trial • Dermatology • Immunology • Vitiligo